Milestone Pharmaceuticals logo
Milestone Pharmaceuticals
MIST | NASDAQ
Chart Builder DCF Calculator
$0.36
-$0.16 (-30.77%)
At close: Nov 16, 2026, 4:00 PM ET
$0.39
+$0.03 (+8.06%)
After-hours: Nov 16, 2026, 7:58 PM ET

Milestone Pharmaceuticals Company Profile

Company profile explained

Company Profile

Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate. Furthermore, Milestone Pharmaceuticals has forged a licensing and collaboration alliance with Ji Xing Pharmaceuticals to advance and distribute etripamil for both preventative and therapeutic applications in humans. The company was founded in 2003.

Key Executives

Name Position
Joseph G. Oliveto Chief Executive Officer, President & Director
Amit Hasija Chief Financial Officer & Executive Vice President of Corporate Development
Jeff Nelson Chief Operating Officer
David Bharucha FACC Chief Medical Officer
David Sandoval General Counsel & Chief Compliance Officer
Guy Rousseau SVP of Regulatory Affairs and Quality Management
Jeff Moore Vice President of Sales
Philip T. Sager FACC FAHA FHRS Chief Medical Advisor & Member of the Scientific Advisory Board
Philippe Douville Founder, Strategic Advisor & Member of Scientific Advisory Board
Roshan Girglani Vice President of Marketing

Latest SEC Filings

Date Type Title
Oct 28, 2026 8-K Current Report
Sep 03, 2026 8-K Current Report
Aug 12, 2026 8-K Current Report
Aug 12, 2026 10-Q Quarterly Report
Aug 07, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Jun 15, 2026 8-K Current Report
Jun 12, 2026 4 Filing
Jun 12, 2026 4 Filing
Jun 12, 2026 4 Filing
Jun 12, 2026 4 Filing
View All SEC Filings ➞
Milestone Pharmaceuticals
Milestone Pharmaceuticals logo
Country Canada
IPO Date May 9, 2019
Industry Biotechnology
Sector Healthcare
Employees 38
CEO Joseph G. Oliveto

Contact Details

1111 Dr. Frederik-Philips Boulevard Montreal, QC H4M 2X6 Canada

Stock Details

Ticker Symbol MIST
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001408443
CUSIP Number 59935V107
ISIN Number CA59935V1076
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.